Loading...
•
Sep 30, 2020
BioCryst Q3 2020 Earnings Report
BioCryst announced financial results for the third quarter ended September 30, 2020.
Key Takeaways
BioCryst announced its third quarter financial results, with total revenues of $6.1 million compared to $1.8 million in the third quarter of 2019. The net loss for the quarter was $46.1 million, or $0.26 per share. The company's cash, cash equivalents, restricted cash and investments totaled $148.5 million at September 30, 2020.
Total revenues were $6.1 million, compared to $1.8 million in the third quarter of 2019.
Research and development (R&D) expenses increased to $30.2 million from $25.1 million in the third quarter of 2019.
Selling, general and administrative (SG&A) expenses increased to $17.2 million, compared to $11.7 million in the third quarter of 2019.
Net loss was $46.1 million, or $0.26 per share, compared to a net loss of $37.6 million, or $0.34 per share, for the third quarter of 2019.
Forward Guidance
BioCryst continues to expect full year 2020 net operating cash use to be in the range of $150 to $165 million, and its operating expenses to be in the range of $180 to $195 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...